The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

The Trump administration continued to reshape US health policy in recent days with several moves that could change what ...

As fired and retired scientists rallied outside in the Atlanta heat, an advisory panel that Robert F. Kennedy Jr. handpicked ...

The most powerful public health official in the US is reviled by some medics - but even some of his critics accept that he is ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The US Advisory Committee on Immunization Practices voted in June to stop recommending certain kinds of flu vaccines, a ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.

A preservative falsely linked to autism became a sticking point during voting for the vaccine committee put together by ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines in the US under new Health and Human Services (HHS) Secretary Robert F ...

The high-dose influenza vaccine elicits stronger immune responses in immunocompromised patients while maintaining a safety profile similar to that of the standard-dose vaccine, a meta-analysis shows.